Comparative Pharmacology
Head-to-head clinical analysis: LOESTRIN FE 1 5 30 versus NORINYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOESTRIN FE 1 5 30 versus NORINYL.
LOESTRIN FE 1.5/30 vs NORINYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Suppresses gonadotropin (FSH and LH) release via estrogen and progestin feedback inhibition, preventing ovulation; increases cervical mucus viscosity and alters endometrial lining.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) provides contraception by inhibiting gonadotropin secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets, then restart.
One tablet (norethindrone 1 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 placebo tablets. For first cycle, start on first Sunday after menstruation begins or on day 1 of menstrual cycle.
None Documented
None Documented
Norethindrone: ~5-14 hours (terminal); Ethinyl estradiol: ~13-27 hours (terminal). Clinically, steady-state achieved within 5-7 days.
Terminal half-life: norethindrone 7-8 hours, ethinyl estradiol 13-27 hours; clinical context: steady-state achieved in 3-5 half-lives
Renal: ~50-60% (norethindrone metabolites); Fecal: ~20-30% (norethindrone); Ethinyl estradiol: primarily renal (~40-50%) and fecal (~20-50%) as glucuronide and sulfate conjugates.
Renal: ~60% as metabolites, biliary/fecal: ~40% as glucuronide conjugates
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive